Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer

Authors not listed

University of Rochester · 2024

Chronic inflammation Human Randomized controlled trial

Abstract

This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-11 MST

Cite this

APA

Anonymous. (2024). A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer. <em>University of Rochester</em>. https://clinicaltrials.gov/study/NCT06068543

Vancouver

Anonymous. A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer. University of Rochester. 2024.

BibTeX

@misc{anon2024APhase, title = {A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer}, author = {Anonymous}, journal = {University of Rochester}, year = {2024}, }